Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04710-1
In the phase 2 UNICORN trial, a short course of neoadjuvant botensilimab and balstilimab achieved the primary endpoint of pathological major response rate in patients with pMMR or dMMR colon cancer.
